Rivian Releases Second Quarter 2025 Financial Results
-
Rivian received$1 billion equity investment fromVolkswagen Group onJune 30th - R2 progress on track; design validation ongoing and testing underway
-
Announced
East Coast headquarters inAtlanta , expected to open later this year
As previously announced, in the second quarter
RJ Scaringe, Rivian Founder and CEO, said:
“This quarter we made significant progress in R2 development and testing. We also substantially completed the expansion of our
Preparations for the launch of R2 currently remain on track. The 1.1 million square foot plant expansion at the
This quarter
In July, in partnership with the
While
The company is maintaining its 2025 delivery guidance range of 40,000 to 46,000. Because of some of the recent changes associated with regulatory credits and its second quarter performance, the company is increasing its guidance for adjusted EBITDA losses to
2025 Guidance |
|
|
Current outlook |
Vehicles Delivered |
40,000 - 46,000 |
Adj. EBITDA |
|
Capital Expenditures |
|
Quarterly Financial Performance | ||||||||||||||||||||
(in millions, except production, delivery, and gross margin amounts) |
||||||||||||||||||||
(unaudited) |
||||||||||||||||||||
|
|
Three Months Ended |
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Production |
|
|
9,612 |
|
|
|
13,157 |
|
|
|
12,727 |
|
|
|
14,611 |
|
|
|
5,979 |
|
Delivery |
|
|
13,790 |
|
|
|
10,018 |
|
|
|
14,183 |
|
|
|
8,640 |
|
|
|
10,661 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Revenues |
|
|
|
|
|
|
|
|
|
|
||||||||||
Automotive |
|
$ |
1,074 |
|
|
$ |
776 |
|
|
$ |
1,520 |
|
|
$ |
922 |
|
|
$ |
927 |
|
Software and services |
|
|
84 |
|
|
|
98 |
|
|
|
214 |
|
|
|
318 |
|
|
|
376 |
|
Total revenues2 |
|
$ |
1,158 |
|
|
$ |
874 |
|
|
$ |
1,734 |
|
|
$ |
1,240 |
|
|
$ |
1,303 |
|
Cost of revenues |
|
|
|
|
|
|
|
|
|
|
||||||||||
Automotive |
|
$ |
1,515 |
|
|
$ |
1,155 |
|
|
$ |
1,410 |
|
|
$ |
830 |
|
|
$ |
1,262 |
|
Software and services |
|
|
94 |
|
|
|
111 |
|
|
|
154 |
|
|
|
204 |
|
|
|
247 |
|
Total cost of revenues2 |
|
$ |
1,609 |
|
|
$ |
1,266 |
|
|
$ |
1,564 |
|
|
$ |
1,034 |
|
|
$ |
1,509 |
|
Gross profit |
|
$ |
(451 |
) |
|
$ |
(392 |
) |
|
$ |
170 |
|
|
$ |
206 |
|
|
$ |
(206 |
) |
Gross margin |
|
|
(39 |
)% |
|
|
(45 |
)% |
|
|
10 |
% |
|
|
17 |
% |
|
|
(16 |
)% |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Research and development |
|
$ |
428 |
|
|
$ |
350 |
|
|
$ |
374 |
|
|
$ |
381 |
|
|
$ |
410 |
|
Selling, general, and administrative |
|
|
496 |
|
|
|
427 |
|
|
|
457 |
|
|
|
480 |
|
|
|
498 |
|
Total operating expenses |
|
$ |
924 |
|
|
$ |
777 |
|
|
$ |
831 |
|
|
$ |
861 |
|
|
$ |
908 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjusted research and development (non-GAAP)1 |
|
$ |
312 |
|
|
$ |
271 |
|
|
$ |
277 |
|
|
$ |
285 |
|
|
$ |
316 |
|
Adjusted selling, general, and administrative (non-GAAP)1 |
|
|
364 |
|
|
|
328 |
|
|
|
343 |
|
|
|
345 |
|
|
|
365 |
|
Total adjusted operating expenses (non-GAAP)1 |
|
$ |
676 |
|
|
$ |
599 |
|
|
$ |
620 |
|
|
$ |
630 |
|
|
$ |
681 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjusted EBITDA (non-GAAP)1,2 |
|
$ |
(857 |
) |
|
$ |
(757 |
) |
|
$ |
(277 |
) |
|
$ |
(329 |
) |
|
$ |
(667 |
) |
Cash, cash equivalents, and short-term investments3 |
|
$ |
7,867 |
|
|
$ |
6,739 |
|
|
$ |
7,700 |
|
|
$ |
7,178 |
|
|
$ |
7,508 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net cash (used in) provided by operating activities |
|
$ |
(754 |
) |
|
$ |
(876 |
) |
|
$ |
1,183 |
|
|
$ |
(188 |
) |
|
$ |
64 |
|
Capital expenditures |
|
|
(283 |
) |
|
|
(277 |
) |
|
|
(327 |
) |
|
|
(338 |
) |
|
|
(462 |
) |
Free cash flow (non-GAAP)1 |
|
$ |
(1,037 |
) |
|
$ |
(1,153 |
) |
|
$ |
856 |
|
|
$ |
(526 |
) |
|
$ |
(398 |
) |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Depreciation and amortization expense |
|
|
|
|
|
|
|
|
|
|
||||||||||
Cost of revenues |
|
$ |
203 |
|
|
$ |
186 |
|
|
$ |
145 |
|
|
$ |
75 |
|
|
$ |
185 |
|
Research and development |
|
|
18 |
|
|
|
20 |
|
|
|
18 |
|
|
|
17 |
|
|
|
17 |
|
Selling, general, and administrative |
|
|
53 |
|
|
|
53 |
|
|
|
55 |
|
|
|
55 |
|
|
|
52 |
|
Total depreciation and amortization expense |
|
$ |
274 |
|
|
$ |
259 |
|
|
$ |
218 |
|
|
$ |
147 |
|
|
$ |
254 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
||||||||||
Cost of revenues |
|
$ |
17 |
|
|
$ |
6 |
|
|
$ |
16 |
|
|
$ |
24 |
|
|
$ |
37 |
|
Research and development |
|
|
98 |
|
|
|
59 |
|
|
|
79 |
|
|
|
79 |
|
|
|
77 |
|
Selling, general, and administrative |
|
|
79 |
|
|
|
46 |
|
|
|
59 |
|
|
|
80 |
|
|
|
81 |
|
Total stock-based compensation expense |
|
$ |
194 |
|
|
$ |
111 |
|
|
$ |
154 |
|
|
$ |
183 |
|
|
$ |
195 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Inventory write-downs |
|
|
|
|
|
|
|
|
|
|
||||||||||
Inventory LCNRV write-downs3 |
|
$ |
148 |
|
|
$ |
130 |
|
|
$ |
66 |
|
|
$ |
23 |
|
|
$ |
48 |
|
Liabilities for losses on firm purchase commitments3 |
|
|
31 |
|
|
|
10 |
|
|
|
5 |
|
|
|
— |
|
|
|
— |
|
Total inventory write-downs and liabilities for losses on firm purchase commitments3 |
|
$ |
179 |
|
|
$ |
140 |
|
|
$ |
71 |
|
|
$ |
23 |
|
|
$ |
48 |
|
1 A reconciliation of non-GAAP financial measures to the most comparable GAAP measure is provided later in this document. |
||||||||||||||||||||
2 The prior periods have been recast to conform to current period presentation. |
||||||||||||||||||||
3 Amount as of date shown. |
Condensed Consolidated Balance Sheets | ||||||||
(in millions, except per share amounts) |
||||||||
(unaudited) |
||||||||
Assets |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
5,294 |
|
|
$ |
4,812 |
|
Short-term investments |
|
|
2,406 |
|
|
|
2,696 |
|
Accounts receivable, net |
|
|
443 |
|
|
|
254 |
|
Inventory |
|
|
2,248 |
|
|
|
2,103 |
|
Other current assets |
|
|
192 |
|
|
|
255 |
|
Total current assets |
|
|
10,583 |
|
|
|
10,120 |
|
Property, plant, and equipment, net |
|
|
3,965 |
|
|
|
4,421 |
|
Operating lease assets, net |
|
|
416 |
|
|
|
493 |
|
Other non-current assets |
|
|
446 |
|
|
|
563 |
|
Total assets |
|
$ |
15,410 |
|
|
$ |
15,597 |
|
|
|
|
|
|
||||
Liabilities and Stockholders’ Equity |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Accounts payable |
|
$ |
499 |
|
|
$ |
489 |
|
Accrued liabilities |
|
|
835 |
|
|
|
1,017 |
|
Current portion of deferred revenues, lease liabilities, and other liabilities |
|
|
917 |
|
|
|
1,437 |
|
Total current liabilities |
|
|
2,251 |
|
|
|
2,943 |
|
Long-term debt |
|
|
4,441 |
|
|
|
4,436 |
|
Non-current lease liabilities |
|
|
379 |
|
|
|
462 |
|
Other non-current liabilities |
|
|
1,777 |
|
|
|
1,677 |
|
Total liabilities |
|
|
8,848 |
|
|
|
9,518 |
|
Commitments and contingencies |
|
|
|
|
||||
Stockholders' equity: |
|
|
|
|
||||
Preferred stock, |
|
|
— |
|
|
|
— |
|
Common stock, |
|
|
1 |
|
|
|
1 |
|
Additional paid-in capital |
|
|
29,866 |
|
|
|
31,028 |
|
Accumulated deficit |
|
|
(23,305 |
) |
|
|
(24,967 |
) |
Accumulated other comprehensive (loss) income |
|
|
(4 |
) |
|
|
6 |
|
Noncontrolling interest |
|
|
4 |
|
|
|
11 |
|
Total stockholders' equity |
|
|
6,562 |
|
|
|
6,079 |
|
|
|
|
|
|
||||
Total liabilities and stockholders' equity |
|
$ |
15,410 |
|
|
$ |
15,597 |
|
Condensed Consolidated Statements of Operations1 | ||||||||||||||||
(in millions, except per share amounts) |
||||||||||||||||
(unaudited) |
||||||||||||||||
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
Automotive |
|
$ |
1,074 |
|
|
$ |
927 |
|
|
$ |
2,190 |
|
|
$ |
1,849 |
|
Software and services |
|
|
84 |
|
|
|
376 |
|
|
|
172 |
|
|
|
694 |
|
Total revenues |
|
|
1,158 |
|
|
|
1,303 |
|
|
|
2,362 |
|
|
|
2,543 |
|
Automotive |
|
|
1,515 |
|
|
|
1,262 |
|
|
|
3,128 |
|
|
|
2,092 |
|
Software and services |
|
|
94 |
|
|
|
247 |
|
|
|
212 |
|
|
|
451 |
|
Total cost of revenues |
|
|
1,609 |
|
|
|
1,509 |
|
|
|
3,340 |
|
|
|
2,543 |
|
Gross profit |
|
|
(451 |
) |
|
|
(206 |
) |
|
|
(978 |
) |
|
|
— |
|
Operating expenses |
|
|
|
|
|
|
|
|
||||||||
Research and development |
|
|
428 |
|
|
|
410 |
|
|
|
889 |
|
|
|
791 |
|
Selling, general, and administrative |
|
|
496 |
|
|
|
498 |
|
|
|
992 |
|
|
|
978 |
|
Total operating expenses |
|
|
924 |
|
|
|
908 |
|
|
|
1,881 |
|
|
|
1,769 |
|
Loss from operations |
|
|
(1,375 |
) |
|
|
(1,114 |
) |
|
|
(2,859 |
) |
|
|
(1,769 |
) |
Interest income |
|
|
95 |
|
|
|
72 |
|
|
|
207 |
|
|
|
153 |
|
Interest expense |
|
|
(75 |
) |
|
|
(69 |
) |
|
|
(150 |
) |
|
|
(141 |
) |
Loss on convertible notes, net |
|
|
(90 |
) |
|
|
— |
|
|
|
(90 |
) |
|
|
— |
|
Other (expense) income, net |
|
|
(11 |
) |
|
|
(2 |
) |
|
|
(9 |
) |
|
|
105 |
|
Loss before income taxes |
|
|
(1,456 |
) |
|
|
(1,113 |
) |
|
|
(2,901 |
) |
|
|
(1,652 |
) |
Provision for income taxes |
|
|
(1 |
) |
|
|
(2 |
) |
|
|
(2 |
) |
|
|
(4 |
) |
Net loss |
|
$ |
(1,457 |
) |
|
$ |
(1,115 |
) |
|
$ |
(2,903 |
) |
|
$ |
(1,656 |
) |
Less: Net income attributable to noncontrolling interest |
|
|
— |
|
|
|
2 |
|
|
|
— |
|
|
|
6 |
|
Net loss attributable to common stockholders |
|
$ |
(1,457 |
) |
|
$ |
(1,117 |
) |
|
$ |
(2,903 |
) |
|
$ |
(1,662 |
) |
Net loss attributable to common stockholders, basic and diluted |
|
$ |
(1,457 |
) |
|
$ |
(1,117 |
) |
|
$ |
(2,903 |
) |
|
$ |
(1,662 |
) |
Net loss per share attributable to Class A and Class B common stockholders, basic and diluted |
|
$ |
(1.46 |
) |
|
$ |
(0.97 |
) |
|
$ |
(2.93 |
) |
|
$ |
(1.45 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
|
1,001 |
|
|
|
1,155 |
|
|
|
990 |
|
|
|
1,146 |
|
1 The prior period has been recast to conform to current period presentation. |
Condensed Consolidated Statements of Cash Flows1 | ||||||||
(in millions) |
||||||||
(unaudited) |
||||||||
|
|
Six Months Ended |
||||||
|
|
|
2024 |
|
|
|
2025 |
|
Cash flows from operating activities: |
|
|
|
|
||||
Net loss |
|
$ |
(2,903 |
) |
|
$ |
(1,656 |
) |
Depreciation and amortization |
|
|
554 |
|
|
|
396 |
|
Stock-based compensation expense |
|
|
427 |
|
|
|
377 |
|
Gain on equity method investment |
|
|
— |
|
|
|
(101 |
) |
Loss on convertible notes, net |
|
|
90 |
|
|
|
— |
|
Other non-cash activities |
|
|
108 |
|
|
|
40 |
|
Changes in operating assets and liabilities: |
|
|
|
|
||||
Accounts receivable, net |
|
|
(88 |
) |
|
|
189 |
|
Inventory |
|
|
(125 |
) |
|
|
108 |
|
Other assets |
|
|
(63 |
) |
|
|
38 |
|
Accounts payable and accrued liabilities |
|
|
(257 |
) |
|
|
120 |
|
Deferred revenues |
|
|
51 |
|
|
|
403 |
|
Other liabilities |
|
|
183 |
|
|
|
(38 |
) |
Net cash used in operating activities |
|
|
(2,023 |
) |
|
|
(124 |
) |
|
|
|
|
|
||||
Cash flows from investing activities: |
|
|
|
|
||||
Purchases of equity securities and short-term investments |
|
|
(2,229 |
) |
|
|
(1,942 |
) |
Sales of short-term investments |
|
|
— |
|
|
|
101 |
|
Maturities of short-term investments |
|
|
1,671 |
|
|
|
1,527 |
|
Capital expenditures |
|
|
(537 |
) |
|
|
(800 |
) |
Net cash used in investing activities |
|
|
(1,095 |
) |
|
|
(1,114 |
) |
|
|
|
|
|
||||
Cash flows from financing activities: |
|
|
|
|
||||
Proceeds from stock-based compensation programs |
|
|
32 |
|
|
|
36 |
|
Proceeds from issuance of capital stock |
|
|
— |
|
|
|
750 |
|
Proceeds from issuance of long-term debt |
|
|
— |
|
|
|
1,250 |
|
Repayments of long-term debt |
|
|
— |
|
|
|
(1,250 |
) |
Proceeds from issuance of convertible notes |
|
|
1,000 |
|
|
|
— |
|
Other financing activities |
|
|
(4 |
) |
|
|
(36 |
) |
Net cash provided by financing activities |
|
|
1,028 |
|
|
|
750 |
|
|
|
|
|
|
||||
Effect of exchange rate changes on cash and cash equivalents |
|
|
(4 |
) |
|
|
6 |
|
Net change in cash |
|
|
(2,094 |
) |
|
|
(482 |
) |
Cash, cash equivalents, and restricted cash—Beginning of period |
|
|
7,857 |
|
|
|
5,294 |
|
Cash, cash equivalents, and restricted cash—End of period |
|
$ |
5,763 |
|
|
$ |
4,812 |
|
|
|
|
|
|
||||
Supplemental disclosure of non-cash investing and financing activities: |
|
|
|
|
||||
Capital expenditures included in liabilities |
|
$ |
365 |
|
|
$ |
452 |
|
Capital stock issued to settle bonuses |
|
$ |
179 |
|
|
$ |
47 |
|
Right-of-use assets obtained in exchange for operating lease liabilities |
|
$ |
87 |
|
|
$ |
134 |
|
1 The prior period has been recast to conform to current period presentation. |
Reconciliation of Non-GAAP Financial Measures | ||||||||||||||||
(in millions) |
||||||||||||||||
(unaudited) |
||||||||||||||||
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Total research and development expenses |
|
$ |
428 |
|
|
$ |
410 |
|
|
$ |
889 |
|
|
$ |
791 |
|
R&D depreciation and amortization expenses |
|
|
(18 |
) |
|
|
(17 |
) |
|
|
(36 |
) |
|
|
(34 |
) |
R&D stock-based compensation expenses |
|
|
(98 |
) |
|
|
(77 |
) |
|
|
(222 |
) |
|
|
(156 |
) |
Adjusted research and development (non-GAAP) |
|
$ |
312 |
|
|
$ |
316 |
|
|
$ |
631 |
|
|
$ |
601 |
|
Adjusted Selling, General, and Administrative Expenses |
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Total selling, general, and administrative expenses |
|
$ |
496 |
|
|
$ |
498 |
|
|
$ |
992 |
|
|
$ |
978 |
|
SG&A depreciation and amortization expenses |
|
|
(53 |
) |
|
|
(52 |
) |
|
|
(105 |
) |
|
|
(107 |
) |
SG&A stock-based compensation expenses |
|
|
(79 |
) |
|
|
(81 |
) |
|
|
(165 |
) |
|
|
(161 |
) |
Adjusted selling, general, and administrative (non-GAAP) |
|
$ |
364 |
|
|
$ |
365 |
|
|
$ |
722 |
|
|
$ |
710 |
|
Adjusted EBITDA1 |
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Net loss attributable to common stockholders |
|
$ |
(1,457 |
) |
|
$ |
(1,117 |
) |
|
$ |
(2,903 |
) |
|
$ |
(1,662 |
) |
Interest income, net |
|
|
(20 |
) |
|
|
(3 |
) |
|
|
(57 |
) |
|
|
(12 |
) |
Provision for income taxes |
|
|
1 |
|
|
|
2 |
|
|
|
2 |
|
|
|
4 |
|
Depreciation and amortization |
|
|
274 |
|
|
|
254 |
|
|
|
554 |
|
|
|
401 |
|
Stock-based compensation expense |
|
|
194 |
|
|
|
195 |
|
|
|
427 |
|
|
|
378 |
|
Other expense (income), net |
|
|
11 |
|
|
|
2 |
|
|
|
9 |
|
|
|
(105 |
) |
Loss on convertible notes, net |
|
|
90 |
|
|
|
— |
|
|
|
90 |
|
|
|
— |
|
Cost of revenue efficiency initiatives |
|
|
29 |
|
|
|
— |
|
|
|
156 |
|
|
|
— |
|
Restructuring expenses |
|
|
— |
|
|
|
— |
|
|
|
30 |
|
|
|
— |
|
Asset impairments and write-offs |
|
|
14 |
|
|
|
— |
|
|
|
14 |
|
|
|
— |
|
Joint venture formation expenses and other items |
|
|
7 |
|
|
|
— |
|
|
|
7 |
|
|
|
— |
|
Adjusted EBITDA (non-GAAP) |
|
$ |
(857 |
) |
|
$ |
(667 |
) |
|
$ |
(1,655 |
) |
|
$ |
(996 |
) |
|
||||||||||||||||
1 The prior periods have been recast to conform to current period presentation. |
About
Learn more about the company, products, and careers at www.rivian.com.
Forward-Looking Statements:
This press release and statements that are made on our earnings call contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release and made on our earnings call that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future operations, initiatives and business strategy, including our future financial results, vehicle profitability and future gross profits, our future capital expenditures, the underlying trends in our business (including customer preferences and expectation), global economic conditions, including evolving trade regulation, policies and tariffs and the resulting impact on our global supply chain and material costs and access, including changes to the availability of government and economic incentives, including tax credits, for electric vehicles, our market opportunity, and our potential for growth, our production ramp and manufacturing capacity expansion and anticipated production levels, our expected future production and deliveries, scaling our service infrastructure, our expected future products and technology and product enhancements including enhanced performance and safety features, and pricing (including the launches of R2 and R3), potential expansion of commercial van sales, future revenue opportunities, including with respect to the emerging autonomous driving market, our joint venture with
*Non-GAAP Financial Measures
In addition to our results determined in accordance with generally accepted accounting principles in
Our non-GAAP financial measures include adjusted research and development expenses, adjusted selling, general, and administrative expenses, adjusted EBITDA, and free cash flow.
Adjusted research and development expenses is defined as total research and development expenses, less R&D depreciation and amortization expenses and R&D stock-based compensation expenses.
Adjusted selling, general, and administrative expenses is defined as total selling, general, and administrative expenses, less SG&A depreciation and amortization expenses and SG&A stock-based compensation expenses.
Adjusted EBITDA defined as net loss before interest expense (income), net, provision for income taxes, depreciation and amortization, stock-based compensation, other (expense) income, net, and special items. Our management team ordinarily excludes special items from its review of the results of the ongoing operations. Special items is comprised of (i) cost of revenue efficiency initiatives which include costs incurred as we transition between major vehicle programs, cost incurred for negotiations with major suppliers regarding changing demand forecasts or design modifications, and other costs for enhancing capital and cost optimization of the Company (ii) restructuring expenses for significant actions taken by the Company, (iii) significant asset impairments and write-offs, and (iv) other items that we do not necessarily consider to be indicative of earnings from ongoing operating activities, including loss (gain) on convertible note, net, and joint venture formation expenses.
Free cash flow is defined as net cash used in operating activities less capital expenditures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250805701359/en/
Investors:
ir@rivian.com
Media:
Source: